Business Wire

QPS Holdings, LLC divests its Neuropharmacology Business Unit

Share

Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO. QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130940694/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

QPS Neuropharmacology facility in Grambach, Austria. (Graphic: Business Wire)

Founded in 1999, QPS Neuropharmacology has built a strong global reputation for high quality services that are deeply scientifically rooted and has an undisputed track-record of serving a loyal and broad customer base globally. This long history of developing expertise within neuropharmacology preclinical studies has contributed to strong year-on-year growth and positioned the organization as a desirable acquisition target. QPS Neuropharmacology is based in a 2,700 m2 state-of-the-art facility in Grambach, Austria, and employs more than 80 employees. With on-site availability of validated transgenic and non-transgenic in-vitro and in-vivo models, QPS Neuropharmacology addresses multiple targets within the growing CNS area and represents a unique partner for biotech and pharma companies in their drug development process.

After the sale is complete, QPS will retain the European clinical division including the service capbilities in Austria, The Czech Republic, and Croatia where QPS has a long history of conducting late-phase clinical trials in neurodegenerative diseases, oncology and various rare diseases. This late-phase clinical capability will remain fully integrated with the QPS global clinical operational services organization, providing comprehensive global CRO services to pharmaceutical and biotech clients worldwide.

“The sale of QPS Neuropharmacology is a natural transition in the development of QPS as a full-service, global CRO focused on preclinical, bioanalysis and clinical research operational services. We believe that the neuropharmacology unit will be strengthened and continue to grow as part of the Scantox organization” saysBen Chien, President and CEO of QPS Holdings, LLC.

Manuela Prokesch, Director of QPS Neuropharmacology, continues: “This is a unique opportunity for us to bring our deep Neuropharmacology expertise to join a preclinical market leader, known for their high quality and customer-centric approach. We are looking forward to continuing to deliver our signature high-quality solutions to our clients while leveraging the synergies we can generate across the Scantox organization”.

QPS Neuropharmacology will continue to serve its valued clients as part of the Scantox organization. The combined company will have more than 300 employees across six sites offering lead optimization, neuropharmacology research services, regulatory toxicology and CMC/analytical services.

Advisors

Perella Weinberg Partners is serving as financial advisor to QPS Holdings, KPMG is serving as its tax advisor and Ropes & Gray together with Wolf Theiss are serving as its legal counsel. Lincoln International is serving as corporate finance advisor to Scantox, EY is serving as its financial and tax advisor, L.E.K. Consulting as its commercial advisor and Accura together with DORDA are serving as its legal counsel.

About QPS Holdings, LLC:

QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe, India and Asia. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.

About Scantox:

Scantox is the leading Nordic pre-clinical GLP-accredited CRO, focused on pharmacology and regulatory toxicology, headquartered in Denmark with three subsidiaries in Sweden and one in Denmark. Based on decades of experience, the company is a trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, with a world known expertise within the Göttingen minipigs. The Company’s services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. Founded in 1977, Scantox is owned by Impilo, a leading Nordic healthcare investment company.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:
Dr. Manuela Prokesch, Director of QPS Neuropharmacology, Manuela.Prokesch@qps.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sinovac Amends Shareholder Rights Plan21.2.2024 08:56:00 CET | Press release

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Categor

41% of Companies “Would Struggle” to Provide CSRD Data21.2.2024 08:22:00 CET | Press release

Some 41% of businesses fear that they would struggle to provide the data required to comply with new regulations.1 According to nShift, the global leader in parcel delivery management software, the longer companies leave starting to track their carbon emissions, the harder it will be to comply. The forthcoming Corporate Sustainability Reporting Directive (CSRD) requires some 50,000 businesses trading with the European Union to track and report on the carbon emissions from their activities. While the exact implementation deadline differs among sectors and countries, experts want that there is no time to waste. Putting off emissions monitoring until later risks creating a “steeper climb to compliance”. Mattias Gredenhag, CTO at nShift said, “The sooner companies start tracking emissions and compiling the required information, the better. For ecommerce and multi-channel retailers, this will include tracking the emissions on shipments. The longer businesses leave it, the steeper the climb

KPN and iBASIS Renew International Services Outsourcing Deal21.2.2024 08:00:00 CET | Press release

iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and KPN, the Netherlands’ leading telecom company, announced today that they have renewed their outsourcing agreement for Voice and Mobile services for three years. Since its sale by KPN in 2019, iBASIS and its global team have been dedicated to bringing KPN best-in-class services, leveraging the group consolidation and economy of scale strategy of its owner, Tofane Global. Cost stability, capacity planning, and fraud prevention have been instrumental in sustaining the Dutch operator’s traffic growth. The renewal underscores the success of iBASIS’ model and long-term relationship with managing KPN’s international traffic growth, including IPX cooperation to handle the surge in mobile data traffic. iBASIS reports an 80% year-on-year growth in Diameter traffic, which has enabled KPN to deliver reliable, high-speed data roaming services to its subscribers. The network scalability has been

Mavenir and Qualcomm to Accelerate 5G High-Density Open vRAN Deployments21.2.2024 08:00:00 CET | Press release

Mavenir, the cloud-native network infrastructure provider building the future of networks, and Qualcomm Technologies, Inc., a leader enabling intelligent computing everywhere, today announce the latest developments in the technology leaders’ strategic collaboration to deliver energy-efficient solutions for high-density cell site configurations that will drive enhanced 5G coverage and capacity in urban areas. The ongoing collaboration is leveraging the Qualcomm® X100 5G RAN Accelerator Card and Mavenir’s Open virtualised Radio Access Network (Open vRAN) solution to accelerate operator deployment of cloud-native, virtualised Open 5G networks – designed to enable enhanced scalability, sustainability, capacity, and efficiency. Mavenir and Qualcomm Technologies’ solution optimises Total Cost of Ownership (TCO) for operators by substantially reducing CPU/core usage and energy consumption requirements through improved power efficiency. This delivers an ideal solution for delivery at scale, in

The Japan Sake and Shochu Makers Association Held the Pairing Dinner with M.O.F.s in Lyon21.2.2024 07:40:00 CET | Press release

The Japan Sake and Shochu Makers Association (JSS), in collaboration with the Union de la Sommellerie Française, hosted a dinner at Institute Lyfe (formerly Paul Bocuse Institute) in Lyon, France, on February 19th at 7 pm. Seven sommeliers who hold the M.O.F. title, an award given to artisans with advanced skills deemed worthy successors of French culture, showcased their expertise by pairing sake with French cuisine. The dinner, attended by approximately 40 professionals in the alcohol industry, paired a selection of six types of sake, ranging from sparkling to aged varieties, with a six-course French meal, including dessert. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240219900827/en/ Sommeliers and sake makers shared a meal at Michelin-starred Restaurant Saisons (Photo: Business Wire) Utsunomiya Hitoshi, the director of the JSS, commented, "It is said that the opportunity for sake to be exported to Europe arose during

HiddenA line styled icon from Orion Icon Library.Eye